Bhusari S Sachin1,
Vandhna Bhat1,
Meenakshi Koul1,
Subhash C Sharma1,
Manoj K Tikoo1,
Ashok K Tikoo1,
Naresh K Satti2,
Krishan A Suri2,
Rakesh K Johri1 
For correspondence:- Rakesh Johri Email: rkjohri@iiim.res.in Tel:+919419132014
Received: 30 April 2009 Accepted: 15 September 2009 Published: 21 December 2009
Citation: Sachin BS, Bhat V, Koul M, Sharma SC, Tikoo MK, Tikoo AK, et al. Development and Validation of a RP-HPLC Method for the Simultaneous Determination of Rifampicin and a Flavonoid Glycoside - A Novel Bioavailability Enhancer of Rifampicin. Trop J Pharm Res 2009; 8(6):531-537 doi: 10.4314/tjpr.v8i6.8
© 2009 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To develop and validate a sensitive HPLC method for the separation and simultaneous estimation of two ingredients in a composition comprising of rifampicin and a flavonoid glycoside (an enhancer of oral bioavailability of rifampicin).
Methods: Reverse phase (RP) chromatographic separation and estimation was achieved using a Shimadzu HPLC system. RP-18 column was used at the following optimised conditions: mobile phase, acetonitrile:phosphate buffer, 50 mM, pH 5.0 in a ratio of 60:40 v/v; oven temperature, 40 0C; flow rate, 0.8 ml min-1; detection wavelength, 340 nm; and total run time, 15 min.
Results: The developed method was validated in terms of linearity, range, accuracy, precision, limit of detection, limit of quantification, robustness and specificity. Good linearity was observed (r2 > 0.999) over the study range of both ingredients. The precision values for rifampicin and the flavonoid glycoside were in the range 1.08-2.77 and 1.14-2.98 %, respectively, while the limit of quantification was 0.10 and 0.05µg mL-1 respectively. The method was found to be robust and specific for both ingredients.
Conclusion: The developed method has a potential application in preclinical and clinical studies.
Archives
News Updates
Fulltext in PDF